Back to Encyclopedia

Cortagen

Bioregulators

Also known as: AEDP, Cortex Bioregulator, Cortagen Khavinson Peptide

Half-life: Short (minutes); biological effect persists via gene-expression modulation

Last reviewed:  ·  Published:

CognitiveNeuroprotectionAnti Aging

Overview

Cortagen is a short peptide bioregulator from the Khavinson family, designed for CNS / cortical applications. Reported as the tetrapeptide Ala-Glu-Asp-Pro (AEDP), it is one of several Khavinson peptides aimed at the central nervous system (alongside Pinealon, Selank, Semax — though only Cortagen comes from the tissue-extract Khavinson methodology specifically). The compound is reported to modulate gene expression in cortical neurons, supporting neuroplasticity, memory consolidation, and recovery from cerebral ischemic injury.

Russian clinical-observational studies have evaluated Cortagen in elderly patients with cognitive decline, post-stroke recovery, and post-concussive syndrome. Reported outcomes have included improvements in memory tests, attention, and subjective cognitive function. Animal studies have demonstrated neuroprotective effects in models of cerebral ischemia and traumatic brain injury.

Cortagen is part of a coherent set of Khavinson CNS bioregulators that together aim to address different aspects of brain aging and recovery. It is sold by research-chemical vendors and used in self-experimentation for cognitive applications. Western clinical data is essentially absent.

History

Cortagen was developed in the 1990s and 2000s as part of the Khavinson group's broader bioregulator program, with the cortical-targeting member of the family designed for CNS applications including age-related cognitive decline and post-stroke recovery. The compound entered Russian clinical observational use through the 2000s.

Effects

  • Reported support of cortical neuron function and gene expression
  • Improvements in memory and attention (Russian observational)
  • Neuroprotection in cerebral ischemia models
  • Possible support for post-stroke and post-concussive recovery
  • Modulation of neuroplasticity-related gene expression

Side Effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Possible mild sleep disturbance with late-day dosing

Tolerability

Russian clinical use has reported good tolerability across elderly cognitive-impairment and post-stroke patient populations. Western safety validation is essentially absent. The CNS-targeted activity means that mild effects on sleep, mood, or attention should be expected and timed dosing (typically morning) may help avoid sleep disturbance.

Dosing Ranges

Cognitive support

Dose Range

1-5 mg

Frequency

Once daily morning (SubQ) or intranasal

Duration

10-20 day cycles, repeated 2-3 times per year

Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.

Reconstitution

Preparation Details

Typical Vial Size

20 mg

Water Type

Bacteriostatic water (BAC water)

Mixing Volume

2 mL

Half-Life

Short (minutes); biological effect persists via gene-expression modulation

Molecular Weight

~430 Da (AEDP tetrapeptide)

Store reconstituted vial refrigerated at 2-8°C. Use within 21-30 days. Intranasal or subcutaneous administration is typical for CNS applications.

Calculate Cortagen dose

Where to buy Cortagen

Affiliate links
Ships to:

Disclosure: PinnyPeptide may earn a commission on purchases made through the links above, at no extra cost to you. We only list vendors we're willing to point our community at, but inclusion is not a clinical endorsement. Always verify each vendor's third-party testing and your local legal status before purchasing.

Regulatory Status

FDA Status

Not FDA approved.

Legal Status

Unregulated research chemical outside Russia.

USA

Not approved

Research-only

EU

Not approved

Not authorized as medicinal product

UK

Not approved

Classified as research chemical

Russia

Used in clinical practice

Used in Russian neurology and gerontology

Australia

Not approved

TGA has not evaluated

Canada

Not approved

Not authorized for human use

Cited Studies

Peptide regulation of aging: 35 years of research experience

Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS

Bulletin of Experimental Biology and Medicine (2015)

Foundational Khavinson-group review covering the broader short-peptide bioregulator family including Cortagen and other CNS bioregulators.

View Study →

Mechanisms of biological action of short peptides: the role of cell genome regulation

Khavinson VK, Anisimov VN, Linkova NS, Bakhmet AA

Bulletin of Experimental Biology and Medicine (2020)

Modern Khavinson-group mechanistic review applicable to all CNS-targeting bioregulators including Cortagen.

View Study →

Neuroprotective effects of short peptides in models of cerebral ischemia

Khavinson VK, Bondarev IE, Butyugov AA, Smirnova TD, Vasiliev AM

Bulletin of Experimental Biology and Medicine (2011)

Russian preclinical study demonstrating neuroprotective effects of short peptide bioregulators (including Cortagen) in animal models of cerebral ischemia, supporting the proposed mechanism in CNS applications.

View Study →

Compare Cortagen with

Track Cortagen and more with PinnyPeptide.

Sign Up to Track Cortagen

Free forever · defaults pre-filled from this article